EnPlusOne Bio provides a flexible enzymatic platform to address the manufacturing limitations currently hindering the acceleration of RNA therapeutics. This platform enables unrestricted synthesis and manufacturing capacity while achieving higher cycle efficiencies for long RNA production. By accessing a broader RNA design space, the company facilitates the incorporation of novel, naturally occurring RNA modifications beyond those accessible through standard chemical synthesis.
Funding
$21.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Traditional chemical synthesis of therapeutic RNA faces challenges in achieving precise nucleotide modifications and scaling production sustainably. Existing methods often rely on harsh chemicals and complex purification processes, limiting the availability of modified RNA for research and clinical applications.
Solution
EnPlusOne has developed the ezRNA synthesis platform, an enzyme-based method for producing therapeutic RNA with diverse nucleotide modifications at commercial scales. This technology leverages the power and flexibility of enzymes to enable precise control over RNA sequence and structure, facilitating the production of customized RNA therapeutics. The ezRNA platform offers a sustainable and scalable solution for RNA manufacturing, addressing the growing demand for modified RNA in the field of RNA therapeutics.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in the development and manufacturing of RNA therapeutics.
Features
- Enzyme-based RNA synthesis for precise nucleotide modification
- Scalable production of therapeutic RNA
- Sustainable manufacturing process
- Customizable RNA sequence and structure